DFW-APIC Government Affairs Committee June 2018

APIC Public Policy and E-News Highlights (2018)

http://cqrcengage.com/apic/home

http://apic.c	ra/Mambar	-Sarvicas/F	Publications	/F-Nows
TILLD.//abic.c	n a/welliber	-3ei vices/f	-upilications	y⊏-ivews

nttp://apio.org/member	Oct vices/F ublications/E-news				
5/10/2018	The 2018 NHSN Patient Safety Component Training videos and slide decks are now available on the NHSN website. All videos and slide PDFs are located on the NHSN training page at: https://www.cdc.gov/nhsn/training/continuing-edu/trainingvideos.html				
	FDA reclassifies sharps needle destruction device: The FDA has reclassified the needle				
	destruction device, now renamed "sharps needle destruction device," from class III				
	(requiring premarket approval) to class II (requiring special controls) to indicate the level of				
	regulatory controls needed to provide reasonable assurance of the safety and effectiveness				
	of the device. The required special controls relate to performance testing, cleaning and				
	disinfection instructions, electromagnetic compatibility and electrical safety, software				
5/10/2018	verification, and labeling. Read the <u>FDA notice</u> .				
	AuraMedics Pharma recalls antibiotic injection vials: AuraMedics Pharma is voluntarily				
	recalling two lots of Piperacillin and Tazobactam for Injection, USP 3.375 g in a single-dose				
	vial and two lots of Ampicillin and Sulbactam for Injection USP, 3 g in a single-dose vial. The				
	products have been found to contain particulate matter in the vials. Read the <u>FDA safety</u>				
- / - /	alert on Piperacillin and Tazobactam. Read the FDA safety alert on the Ampicillin and				
5/10/2018	Sulbactam recall				
	Multistate outbreak of <i>B. cepacia</i> The CDC reported ten confirmed cases of infection caused by bacteria within the				
	Burkholderia cepacia complex in California, Pennsylvania, and New Jersey. The patients				
F/16/2019					
5/10/2018					
5/30/18	affected area. Read the CDC update				
5/16/2018	acquired the infections while already hospitalized for acute conditions. The infections have been linked to the Medline product, Remedy Essentials No-Rinse Cleansing Foam. Shadow Holdings dba Bocchi Laboratories has voluntarily recalled 4 ounce and 8 ounce bottles of the lots that tested positive for the bacteria. Read the FDA safety alert. CDC provides update on Ebola outbreak in Congo The CDC is continuing to monitor information about the current outbreak of Ebola virus disease (EVD). The WHO Emergency Committee has determined that the current outbreak has not met the conditions for a Public Health Emergency of International Concern, so international travel and trade restrictions are not recommended. The CDC is advising U.S. healthcare providers to continue to obtain travel histories from all patients seeking care, and promptly isolate patients that have symptoms compatible with EVD and recent travel to the				

Texas Register (2018)

http://www.sos.state.tx.us/texreg/index.shtml							
Last Review Completed:			6/1/2018				
Current Search F	Parameters for Review:						
25 TAC: Chapters	25 TAC: Chapters 2, 97, 133, 135, 200						
30 TAC: Chapter 330; Subchapter Y				Key: X Pending			
X	Date Filed	Action	Title/Ch./Rules	Topic / Comments			
				Amendment to comply with H.B. 2886,			
				which amended Texas Health & Safety Code			
				§81.09 - Provides an exception for certain			
				health care providers who are unable to			
				apply prophylaxis against ophthalmia			
				neonatorum due to objection of parent,			
				managing conservator, or guardian of the			
				newborn infant. The HCP doesn't commit			
				an offence & is not subject to criminal, civil,			
				or administrative liability or professional			
				disciplinary action. The objection must be			
	5/17/2018	Adopted	25 TAC §97.136	entered into the infant's medical record.			

Prepared by 2018 APIC-DFW Governmental Affairs Committee: Jasmine Cluck, Heather Kirby, Patti Grant, Stephanie Kreiling